Delving into the Latest Updates on Centenary Institute of Cancer Medicine and Cell Biology with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

MLPH(melanophilin)	1

The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination.
The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?

Start Date23 Nov 2023

Sponsor / Collaborator

South Australian Health & Medical Research Institute Ltd.

[+5]

100 Clinical Results associated with Centenary Institute of Cancer Medicine and Cell Biology

Login to view more data

0 Patents (Medical) associated with Centenary Institute of Cancer Medicine and Cell Biology

Login to view more data

454

Literatures (Medical) associated with Centenary Institute of Cancer Medicine and Cell Biology

01 Apr 2025·Cell Stem Cell

A cloaked human stem-cell-derived neural graft capable of functional integration and immune evasion in rodent models

Article

Author: Quattrocchi, Andrew T ; Parish, Clare L ; Thompson, Lachlan H ; Pavan, Chiara ; Berrocal Rubio, Miguel Á ; Payne, Natalie ; Elahi, Zahra ; Nagy, Andras ; Frausin, Stefano ; Hunt, Cameron P J ; Moriarty, Niamh ; Wells, Christine A ; Abu-Bonsrah, Kwaku Dad ; Davidson, Kathryn C ; Pellegrini, Marc ; Clow, William ; Wang, Le ; Yang, Huijuan

Human pluripotent stem cell (hPSC)-derived therapies are a realistic possibility for numerous disorders, including Parkinson's disease. While generating replacement neurons is achievable, immunosuppressive drug challenges, to prevent rejection, remain. Here we adopted a hPSC line (termed H1-FS-8IM), engineered to overexpress 8 immunomodulatory transgenes, to enable transplant immune evasion. In co-cultures, H1-FS-8IM PSC-derived midbrain neurons evaded rejection by T lymphocytes, natural killer cells, macrophages, and dendritic cells. In humanized mice, allogeneic H1-FS-8IM neural grafts evaded rejection, while control hPSC-derived neural grafts evoked activation of human immune cells, elevated inflammatory cytokines in blood and cerebrospinal fluid, and caused spleen and lymph node enlargement. H1-FS-8IM neural grafts retained functionality, reversing motor deficits in Parkinsonian rats. Additional incorporation of a suicide gene into the H1-FS-8IM hPSC line enabled proliferative cell elimination within grafts. Findings demonstrate feasibility of generating a population-wide applicable, safe, off-the-shelf cell product, suitable for treating diseases for which cell-based therapies are a viable option.

31 Dec 2024·OncoImmunology

MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4 ⁺ T cells in vivo

Article

Author: Terry, Alexandra M. ; McGuire, Helen M. ; Fazekas de St Groth, Barbara ; Shklovskaya, Elena ; Guy, Thomas V.

There has been growing interest in the role of B cells in antitumour immunity and potential use in adoptive cellular therapies. To date, the success of such therapies is limited. The intrinsic capacity of B cells to specifically activate tumour-specific CD4+ T cells in vivo via TCR-dependent interactions remains poorly defined. We have developed an in vivo tumour model that utilizes MHCII I-E restriction which limits antigen presentation to tumour-specific CD4 T cells to either tumour-specific B cells or host myeloid antigen presenting cells (APCs) in lymphopenic RAG-/-mice. We have previously shown that these naive tumour-specific CD4+ T cells can successfully eradicate established tumours in this model when activated by host APCs. When naïve tumour-specific B cells are the only source of I-E+ APC, very limited proliferation of naïve CD4+ T cells is observed, whereas host I-E+ APCs are potent T cell activators. B cells pre-activated with an anti-CD40 agonistic antibody in vivo support increased T cell proliferation, although far less than host APCs. CD4+ T cells that have already differentiated to an effector/central memory phenotype proliferate more readily in response to naïve B cells, although still 100-fold less than in response to host APCs. This study demonstrates that even in a significantly lymphopenic environment, myeloid APCs are the dominant primary activators of tumour-specific T cells, in contrast to the very limited capacity of tumour-specific B cells. This suggests that future anti-tumour therapies that incorporate activated B cells should also include mechanisms that activate host APCs.

01 May 2024·Liver Transplantation

The incidence of adverse outcome in donors after living donor liver transplantation: A meta-analysis of 60,829 donors

Article

Author: Liu, Ken ; Tan, Eunice XX ; Ong, Elden Yen Hng ; Koh, Jia Hong ; Danpanichkul, Pojsakorn ; Kow, Alfred Wei Chieh ; Tan, Darren Jun Hao ; Teng, Margaret ; Zeng, Rebecca Wenling ; Siddiqui, Mohammad Shadab ; Lee, Shi Yan ; Prakash, Sameer ; Syn, Nicholas ; Tay, Phoebe ; Ng, Cheng Han ; Ong, Christen En Ya ; Xiao, Jieling ; Fu, Clarissa Elysia ; Kulkarni, Anand V. ; Chung, Charlotte Hui ; Wijarnpreecha, Karn ; Muthiah, Mark D. ; Huang, Daniel Q. ; Yong, Jie Ning ; Lim, Wen Hui

The scarcity of liver grafts has prompted developments in living donor liver transplantations (LDLT), with previous literature illustrating similar outcomes in recipients compared to deceased donor transplants. However, significant concerns regarding living donor morbidity and mortality have yet to be examined comprehensively. This study aims to provide estimates of the incidence of various outcomes in living liver donors. In this meta-analysis, Medline and Embase were searched from inception to July 2022 for articles assessing the incidence of outcomes in LDLT donors. Complications in the included studies were classified into respective organ systems. Analysis of incidence was conducted using a generalized linear mixed model with Clopper-Pearson intervals. Eighty-seven articles involving 60,829 living liver donors were included. The overall pooled incidence of complications in LDLT donors was 24.7% (CI: 21.6%–28.1%). The incidence of minor complications was 17.3% (CI: 14.7%–20.3%), while the incidence of major complications was lower at 5.5% (CI: 4.5%–6.7%). The overall incidence of donor mortality was 0.06% (CI: 0.0%–0.1%) in 49,027 individuals. Psychological complications (7.6%, CI: 4.9%–11.5%) were the most common among LDLT donors, followed by wound-related (5.2%, CI: 4.4%–6.2%) and respiratory complications (4.9%, CI: 3.8%–6.3%). Conversely, cardiovascular complications had the lowest incidence among the subgroups at 0.8% (CI: 0.4%–1.3%). This study presents the incidence of post-LDLT outcomes in living liver donors, illustrating significant psychological, wound-related, and respiratory complications. While significant advancements in recent decades have contributed towards decreased morbidity in living donors, our findings call for targeted measures and continued efforts to ensure the safety and quality of life of liver donors post-LDLT.

100 Deals associated with Centenary Institute of Cancer Medicine and Cell Biology

Login to view more data

100 Translational Medicine associated with Centenary Institute of Cancer Medicine and Cell Biology

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

Other

Login to view more data